Summary
In nearly 10,000 healthy adults over the age of 70, atorvastatin reduced major cardiovascular events by 30% but failed to produce a statistically significant improvement in disability-free survival—survival without death, dementia, or persistent disability—over nearly six years of follow-up. The study uncouples two endpoints long treated as synonymous in primary care: safeguarding the vasculature and preserving functional, independent years.
The Unspoken Question Every Patient Over 70 Asks
Picture a quintessential patient familiar to any practicing clinician: a 76-year-old woman who walks her dog twice daily and has never suffered a cardiovascular event. Her LDL cholesterol runs mildly elevated, and her blood pressure is well controlled. On the computer screen, the cardiovascular risk calculator nudges the dial toward initiating a statin. At that precise moment, she voices the question lingering in the minds of so many older adults: “Will this medication keep me out of a nursing home?”
For decades, medicine answered this question by extrapolating midlife trial data into advanced age: if statins prevent myocardial infarction in middle age, the reasoning went, they must also confer additional healthy, functional years later in life. Yet adults over 70 were starkly underrepresented in the landmark clinical trials that formed the foundation of our clinical guidelines. A rigorous, large-scale randomized trial has finally tested this assumption head-on. The answer it delivers is neither as straightforward as statin advocates had hoped nor as dismissive as skeptics might have wagered; instead, it paints a considerably more nuanced clinical picture.
The Study
STAREE was a double-blind, placebo-controlled trial conducted through primary care practices. Investigators enrolled 9,971 community-dwelling adults aged 70 and older without prior cardiovascular disease, diabetes, or dementia, randomizing 4,984 participants to receive atorvastatin 40 mg daily and 4,987 to a matching placebo. The mean age was 74.7 years, 51.9% were women, and the median follow-up was 5.9 years[1].
The trial design featured a hierarchical coprimary endpoint framework. The first was a conventional cardiovascular composite endpoint encompassing cardiovascular death, nonfatal myocardial infarction, stroke, or coronary revascularization. The second was a geriatric composite endpoint defined as death from any cause, dementia, or persistent physical disability. This second endpoint is particularly crucial: it directly measures the outcome older patients value most, while addressing a critical…
ŞA
Medically reviewed by
Dr. Şekip Altunkan
Dr. Şekip Altunkan is an internal medicine specialist with extensive clinical experience. He trained at Hacettepe University Faculty of Medicine and later served as an Associate Professor in Internal Medicine. He founded and led the Metropol Internal Medicine and Hypertension Clinic in Ankara, pioneering non-invasive Electron Beam Tomography (EBT) cardiac imaging, arterial-stiffness measurement, and nationwide Holter monitoring. He currently practices at his private clinic in Ankara, focusing on hypertension, vascular health, cholesterol, diabetes and heart disease. He has published widely in national and international journals, serves as a peer reviewer for several international journals, and is the author of the book "Questions and Answers on Hypertension."
